Key facts
- CuroTis’s last known valuation is $15.7M (Jan 2025).
- It has raised $4.4M; the latest was Later Stage VC ($1.1M) in Jan 2025.
- Notable investors include High-Tech Gründerfonds, Rijksdienst voor Ondernemend Nederland, Limburg Development and Investment Company, Brightlands Venture Partners, GIMIC Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for CuroTis
- ·The full record, as it builds
Funding rounds
No funding rounds for CuroTis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CuroTis
Developer of a tissue engineering technology designed for novel therapeutic options for vascular surgery. The company's platform uses a synthetic rod with a specialized surface that is inserted under the skin, inducing the body to form a tissue capsule that matures into a functional blood vessel that is used as a vascular access site for hemodialysis, enabling physicians to create autologous blood vessels that are protected from foreign materials.
- Sector
- Healthcare
- HQ
- Maastricht, Netherlands
- Founded
- 2016
- Employees
- 6
- Website
- curotis.com/
- Ownership
- Privately Held (backing)
CuroTis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CuroTis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CuroTis in its N-PORT filings yet. We sweep new filings monthly.